Miyastenia Gravis Hastalarında Anestezi Yönetimi
Özet
Miyastenia Gravis (MG), iskelet kaslarındaki nöromüsküler iletimi etkileyen ve istemli kaslarda dalgalı güçsüzlüğe yol açan otoimmün bir hastalıktır. Bu durum, asetilkolin reseptörlerine karşı gelişen antikorların reseptör sayısını ve fonksiyonunu azaltmasıyla ortaya çıkar. Cerrahi süreçlerde MG hastaları için en kritik riskler; solunum yetmezliği, aspirasyon ve anestezi ilaçlarıyla (özellikle kas gevşeticilerle) yaşanan etkileşimlerdir. Güvenli bir anestezi yönetimi için preoperatif dönemde hastanın kas gücü ve solunum fonksiyonları titizlikle değerlendirilmelidir. Ameliyatın, semptomların kontrol altında olduğu remisyon dönemlerinde planlanması önerilir. İntraoperatif süreçte, nöromüsküler bloke edici ajanlardan mümkün olduğunca kaçınılmalı veya dozları %50 oranında azaltılarak TOF monitörizasyonu eşliğinde kullanılmalıdır. Modern anestezide roküronyum etkisinin sugammadeks ile hızlıca geri döndürülebilmesi önemli bir avantaj sağlar. Postoperatif dönemde ise hastalar miyastenik kriz ve solunum komplikasyonları açısından yoğun bakım veya servis ortamında yakından takip edilmelidir. Ağrı yönetiminde opioidlerin solunumu baskılayıcı etkisinden korunmak adına bölgesel bloklar veya NSAİİ’ler tercih edilmelidir. Başarılı bir yönetim, multidisipliner bir yaklaşım ve kişiselleştirilmiş anestezi stratejileri ile mümkündür.
Myasthenia Gravis (MG) is an autoimmune disease that affects neuromuscular transmission in skeletal muscles, leading to fluctuating weakness in voluntary muscles. This condition occurs when antibodies against acetylcholine receptors reduce the number and function of these receptors. The most critical risks for MG patients during surgical procedures include respiratory failure, aspiration, and interactions with anesthetic drugs, particularly muscle relaxants. For safe anesthesia management, the patient's muscle strength and respiratory functions must be meticulously evaluated in the preoperative period. It is recommended to plan surgery during remission periods when symptoms are well-controlled. During the intraoperative phase, neuromuscular blocking agents should be avoided if possible or used with a 50% dose reduction under TOF monitoring. In modern anesthesia, the rapid reversal of rocuronium's effect with sugammadex provides a significant advantage. In the postoperative period, patients should be closely monitored in intensive care or ward settings for myasthenic crisis and respiratory complications. To avoid the respiratory depressive effects of opioids in pain management, regional blocks or NSAIDs should be preferred. Successful management is possible through a multidisciplinary approach and personalized anesthesia strategies.
Referanslar
Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25):1797-1810.
Hirsch NP. Neuromuscular junction in health and disease. Br J Anaesth. 2007;99(1):132-138.
Pascuzzi RM. The history of myasthenia gravis. Neurologic clinics. 1994;12(2):231-242.
Hansen JS, Danielsen DH, Somnier FE, et al. Mortality in myasthenia gravis: A nationwide population-based follow-up study in Denmark. Muscle Nerve. 2016;53(1):73-77.
Aminoff M, Greenberg D, Simon R. Motor deficits. Clinical neurology 6th Ed Philadelphia: The McGraw-Hill. 2005:176-220.
Hohlfeld R, Wekerle H. The role of the thymus in myasthenia gravis. Advances in neuroimmunology. 1994;4(4):373-386.
Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570-2581.
Maselli RA. Pathophysiology of myasthenia gravis and Lambert-Eaton syndrome. Neurol Clin. 1994;12(2):285-303.
Papazian O. Transient neonatal myasthenia gravis. J Child Neurol. 1992;7(2):135-141.
Abel M, Eisenkraft JB. Anesthetic implications of myasthenia gravis. Mt Sinai J Med. 2002;69(1-2):31-37.
Thorlacius S, Aarli JA, Riise T, et al. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand. 1989;80(4):290-295.
Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology. 2012;78(20):1601-1607.
Gotaas HT, Skeie GO, Gilhus NE. Myasthenia gravis and amyotrophic lateral sclerosis: A pathogenic overlap. Neuromuscular Disorders. 2016;26(6):337-341.
Nicolle MW. Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome. Continuum (Minneap Minn). 2016;22(6, Muscle and Neuromuscular Junction Disorders):1978-2005.
Elrod RD, Weinberg DA. Ocular myasthenia gravis. Ophthalmology clinics of North America. 2004;17(3):275-309; v.
Hetherington KA, Losek JD. Myasthenia gravis: myasthenia vs. cholinergic crisis. Pediatric emergency care. 2005;21(8):546-548.
Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52(10):1121-1127.
Chan KH, Lachance DH, Harper CM, et al. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36(5):651-658.
Oh SJ, Jeong D, Lee I, et al. Repetitive nerve stimulation test in myasthenic crisis. Muscle Nerve. 2019;59(5):544-548.
Bernstein LP, Antel JP. Motor neuron disease: decremental responses to repetitive nerve stimulation. Neurology. 1981;31(2):202-202.
Muckler VC, O'Brien JM, Matson SE, et al. Perianesthetic Implications and Considerations for Myasthenia Gravis. Journal of PeriAnesthesia Nursing. 2019;34(1):4-15.
Pascuzzi RM. The edrophonium test. Semin Neurol. 2003;23(1):83-88.
FDA. [Available from: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Edrophonium+Chloride+%28ENLON%29+Injection%2C+USP&st=d&tab=tabs-2.
Juel VC, Massey JM. Myasthenia gravis. Orphanet journal of rare diseases. 2007;2(1):44.
Marschall K. Skin and musculoskeletal diseases. Stoelting’s anesthesia and co-existing disease 7th ed Philadelphia: Elsevier. 2018:507-537.
Jamal BT, Herb K. Perioperative management of patients with myasthenia Gravis: prevention, recognition, and treatment. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2009;107(5):612-615.
Kes P, Bašić-Kes V. Plasmapheresis and specific immunoadsorption in the treatment of myasthenia gravis. Acta Clin Croat. 2001;40(1):39-41.
Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. Jama. 2004;291(19):2367-2375.
Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmunity reviews. 2013;12(9):875-884.
Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. European journal of neurology. 2014;21(5):687-693.
Rubino FA. Perioperative management of patients with neurologic disease. Neurologic clinics. 2004;22(2):261-276.
Epstein JH, Eisenkraft JB. Myasthenia gravis. Clinical Cases in Anesthesia2014. p. 111-115.
Blichfeldt-Lauridsen L, Hansen BD. Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand. 2012;56(1):17-22.
Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration*. Anesthesiology. 2017;126(3):376-393.
Katz JA, Murphy GS. Anesthetic consideration for neuromuscular diseases. Curr Opin Anaesthesiol. 2017;30(3):435-440.
Sinha A, Ahmad K, Harrop-Griffiths W. The use of a vertical infraclavicular brachial plexus block in a patient with myasthenia gravis: effects on lung function. Anaesthesia. 2001;56(2):165-168.
Urban MK. Muscle diseases. Anesthesia and uncommon diseases: Elsevier; 2012. p. 296-318.
Lal J, Bansal T. Myasthenia gravis: Anaesthetic implications and considerations-a report of two cases. Cumhuriyet Medical Journal. 2016;38(3):219-222.
Gritti P, Sgarzi M, Carrara B, et al. A standardized protocol for the perioperative management of myasthenia gravis patients. Experience with 110 patients. Acta Anaesthesiol Scand. 2012;56(1):66-75.
Gritti P, Carrara B, Khotcholava M, et al. The use of desflurane or propofol in combination with remifentanil in myasthenic patients undergoing a video-assisted thoracoscopic-extended thymectomy. Acta Anaesthesiol Scand. 2009;53(3):380-389.
Naguib M, Lien CA, Meistelman C. Pharmacology of neuromuscular blocking drugs. Millers. 2015:982.
Nilsson E, Meretoja OA. Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis. Anesthesiology. 1990;73(1):28-32.
Gotterer L, Li Y. Maintenance immunosuppression in myasthenia gravis. Journal of the Neurological Sciences. 2016;369:294-302.
Turáni E, Szathmáry I, Molnár J, et al. Myasthenia gravis: prognostic significance of clinical data in the prediction of post-thymectomy respiratory crises. Acta Chir Hung. 1992;33(3-4):353-360.
Haroutiunian S, Lecht S, Zur AA, et al. The challenge of pain management in patients with myasthenia gravis. Journal of pain & palliative care pharmacotherapy. 2009;23(3):242-260.
Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol. 2004;24(1):75-81.
Kadota Y, Horio H, Mori T, et al. Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014. General Thoracic and Cardiovascular Surgery. 2015;63(4):201-215.
